COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-MWT Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of MRI on Cardiac Remodeling

Trial Profile

COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-MWT Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of MRI on Cardiac Remodeling

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Mar 2014

At a glance

  • Drugs Bosentan (Primary) ; Sildenafil
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms COMPASS-3
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 25 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top